Any current/future new fundraising through debt or equity?

Primarily, Dishman Carbogen Amcis Limited plans to fund upcoming investments through internal accruals and operational cash flow. There might be fundraising in the future, but only at the right valuation and after considering all relevant factors. Currently, there is no definitive plan to raise funds through new debt or equity; emphasis is on using internal cash flow. Regarding current debt, they are focused on reducing higher-cost debt in India (about INR 750 crores) using free cash flow. No explicit mention of immediate or planned debt or equity fundraising beyond these points in the near te

Any current/future capex/capital investment/strategic investment?

Dishman Carbogen Amcis is undertaking co-investment projects with a Japanese customer to ramp up capacity for ADC linker payload supplies, expected to complete in about 1.5 years (Page 13). The company plans significant ramp-up in revenues from this co-investment, with expectations of CHF 30-40 million incremental revenue in coming years (Page 14). The French facility, with ~EUR 50 million (~INR 500 crore) investment, started operations recently and is expected to ramp up and reach breakeven next financial year (Page 24). The India site has seen investments of about INR 300 crore, with a large

Future growth expectations in sales/revenue/volumes?

Expect significant ramp-up in India operations with INR 1,200 crores worth of RFPs submitted; 30-35% expected conversion into orders within 6 months, targeting INR 500 crores revenue in next 12-18 months and INR 800 crores in 3-5 years. Swiss entity aims to double development revenue over next 5 years by securing more initial phase and phase III projects. French subsidiary plans breakeven next financial year, with FY27 revenue projected at ~EUR 18 million and increasing interest/orders. Shanghai facility targeting pharmaceutical market in China with recently obtained local FDA certificat

Future growth expectations in earnings/operating earnings/profits/EPS?

The company targets to improve consolidated EBITDA margins from around 20% in FY26 to 25-26% within the next two years and aims to reach 30% by 2030. Revenues from key blockbuster ADC molecules are expected to ramp up significantly over the next 3-5 years, driven by additional indications and breakthrough therapy designations. The French facility is expected to break even in FY27 with revenues rising to approximately EUR 18 million. India site utilization is targeted to increase 2.5x within 2-3 years, with revenue expected to rise from the current base towards INR 500 crores in 12-18 mon

Current/ Expected Orderbook/ Pending Orders?

Dishman Carbogen Amcis has submitted approximately INR 1,200 crores worth of RFPs (Requests for Proposals) from the India site. The expected conversion rate of these RFPs into orders is about 30% to 35%. Orders converted from RFPs are anticipated to be supplied mostly within the next 12 to 18 months. The India site aims to reach INR 500 crores in revenue within 12 to 18 months and INR 800 crores in the subsequent 3-5 years. For the Japanese ADC customer, there is a confirmed visibility of revenues over the next three years, supported by ongoing co-investment. The company is pursuing multiple r

IN US

Sale is live|00:00:00left today

Dishman Carbogen Amcis LtdQ4 FY27Pharmaceuticals & Biotechnology

Dishman Carbogen Amcis Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹173P/E: 23.1Market Cap: ₹3.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

Yes

Capex

Yes

4 of 5 growth signals are positive — a strong management growth story.

Full analysis

Revenue guidance

Category 3

→Expect significant ramp-up in India operations with INR 1,200 crores worth of RFPs submitted; 30-35% expected conversion into orders within 6 months, targeting INR 500 crores revenue in next 12-18 months and INR 800 crores in 3-5 years.
→Swiss entity aims to double development revenue over next 5 years by securing more initial phase and phase III projects.
→French subsidiary plans breakeven next financial year, with FY27 revenue projected at ~EUR 18 million and increasing interest/orders.
→Shanghai facility targeting pharmaceutical market in China with recently obtained local FDA certification; utilization expected to rise from 50% to ~75%.
→Supply of ADC drug molecules expected to grow strongly, with blockbuster drugs expanding indications, increasing volumes over next 3-5 years.
→Overall, full year EBITDA margin target remains around 20%, with long-term goal of 25-26% consolidated margin by 2028 and 30% by 2030.

Margin guidance

Category 1

→The company targets to improve consolidated EBITDA margins from around 20% in FY26 to 25-26% within the next two years and aims to reach 30% by 2030.
→Revenues from key blockbuster ADC molecules are expected to ramp up significantly over the next 3-5 years, driven by additional indications and breakthrough therapy designations.
→The French facility is expected to break even in FY27 with revenues rising to approximately EUR 18 million.
→India site utilization is targeted to increase 2.5x within 2-3 years, with revenue expected to rise from the current base towards INR 500 crores in 12-18 months and INR 800 crores in 3-5 years.
→The Swiss entity plans to double development revenue over the next five years by securing early-stage projects and phase III supplies.
→Overall, revenue growth and margin expansion are expected to be driven by operational ramp-up, new orders, and capacity utilization improvements.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Primarily, Dishman Carbogen Amcis Limited plans to fund upcoming investments through internal accruals and operational cash flow.
→There might be fundraising in the future, but only at the right valuation and after considering all relevant factors.
→Currently, there is no definitive plan to raise funds through new debt or equity; emphasis is on using internal cash flow.
→Regarding current debt, they are focused on reducing higher-cost debt in India (about INR 750 crores) using free cash flow.
→No explicit mention of immediate or planned debt or equity fundraising beyond these points in the near term.

Order book

Yes

→Dishman Carbogen Amcis has submitted approximately INR 1,200 crores worth of RFPs (Requests for Proposals) from the India site.
→The expected conversion rate of these RFPs into orders is about 30% to 35%.
→Orders converted from RFPs are anticipated to be supplied mostly within the next 12 to 18 months.
→The India site aims to reach INR 500 crores in revenue within 12 to 18 months and INR 800 crores in the subsequent 3-5 years.
→For the Japanese ADC customer, there is a confirmed visibility of revenues over the next three years, supported by ongoing co-investment.
→The company is pursuing multiple rounds of co-investments and capacity expansions, indicating a growing order pipeline.
→RFPs in Switzerland include both early-phase and commercial production, with some commercial-scale orders expected soon.

Capex plans

Yes

→Dishman Carbogen Amcis is undertaking co-investment projects with a Japanese customer to ramp up capacity for ADC linker payload supplies, expected to complete in about 1.5 years (Page 13).
→The company plans significant ramp-up in revenues from this co-investment, with expectations of CHF 30-40 million incremental revenue in coming years (Page 14).
→The French facility, with ~EUR 50 million (~INR 500 crore) investment, started operations recently and is expected to ramp up and reach breakeven next financial year (Page 24).
→The India site has seen investments of about INR 300 crore, with a large focus on filling up capacities via submitted RFPs worth ~INR 1,200 crore; target revenue from India is INR 500 crore in next 12-18 months and INR 800 crore over 3-5 years (Pages 12-13, 24).
→Over the next three years, internal accruals will primarily fund further investments; fundraising may be considered depending on valuation and conditions (Page 33).

How does Dishman Carbogen Amcis Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Dishman Carbogen Amcis Ltd

Rev 3Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Dishman Carbogen Amcis Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio